Imugene (ASX; IMU) is an immuno-oncology focused biopharmaceutical company developing HER-2+ gastric and breast cancer immunotherapies.
View Imugene COO Leslie Chong presenting at Noble Financial Capital Markets' Annual Conference Jan 20 16 (click here) and being interviewed on US based investment program - "The Red Chip Money Report" (click here). View interview on Sky Business News (14 July 2015) (click here) and presentation (click here) by Imugene Director Dr Axel Hoos.
Our lead product is HER-Vaxx, a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the $US6.9 billion per annum drug Herceptin®.
Click here to view latest 2-page flyer (January 2016)
Click here to view video that introduces HER-Vaxx and explains how it works
Click here to view Imugene's current share price
Click here to view cancer vaccines article featuring Imugene and HER-Vaxx
HER-Vaxx has successfully completed a Phase 1 study in breast cancer and the next stage of development will be a Phase 2 study in gastric cancer. Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer, with over 1,000,000 new cases diagnosed each year.
HER-Vaxx has shown success in stimulating the production of lifesaving HER-2 antibodies in early-stage cancer patients enrolled in the initial clinical trial. Its further development is directed towards providing a natural, potentially more potent alternative to Roche’s popular injectable antibody, Herceptin®, which has become one of the world’s bestselling cancer drugs with annual sales in excess of $US6.9 billion (CHF6.08 billion, Roche Investor Update 30/1/14).
Imugene’s corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria.